deferiprone

Known as: 1,2-dimethyl-3-hydroxypyrid-4-one, DMOHPO, 1,2-dimethyl-3-hydroxypyridin-4-one 
An orally bioavailable bidentate ligand with iron chelating activity. Deferiprone binds to iron in a 3:1 (ligand:iron) molar ratio. By binding to… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2007
Highly Cited
2007
BACKGROUND Cardiac complications secondary to iron overload are the leading cause of death in beta-thalassemia major… (More)
  • figure 1
  • figure 2
  • figure 4
  • figure 3
  • figure 5
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Most deaths in beta-thalassemia major result from cardiac complications due to iron overload. Differential effects on myocardial… (More)
  • figure 1
  • table 1
  • figure 3
  • figure 2
Is this relevant?
Review
2006
Review
2006
For nearly 30 years, patients with transfusional iron overload have depended on nightly deferoxamine infusions for iron chelation… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Deferoxamine (DFO) therapy has been associated with improved survival of thalassemia patients. However, cardiac disease remains… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2003
Highly Cited
2003
The identification of a safe, orally active iron chelator is critically important for the prevention of morbidity and early death… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
Is this relevant?
Highly Cited
2002
Highly Cited
2002
In 1997, the Italian Ministry of Health created a special programme for the controlled distribution of deferiprone to collect… (More)
Is this relevant?
Highly Cited
2000
Highly Cited
2000
In previous trials, the orally active iron chelator deferiprone (L1) has been associated with sporadic agranulocytosis, milder… (More)
Is this relevant?
Highly Cited
1998
Highly Cited
1998
In a proportion of transfusion-dependent patients iron chelation with daily doses of deferiprone of 75 mg/kg body weight (b.w… (More)
Is this relevant?
Review
1997
Review
1997
Iron-chelating therapy with deferoxamine in patients with thalassemia major has dramatically altered the prognosis of this… (More)
Is this relevant?
Highly Cited
1995
Highly Cited
1995
BACKGROUND To determine whether the orally active iron chelator deferiprone (1,2-dimethyl-3-hydroxy-pyridin-4-one) is efficacious… (More)
Is this relevant?